2.1. Study Design
Diabetes
MAY, SECONDARY, DIABETES
This report is a secondary analysis of a randomized, double-blind, placebo-controlled study that demonstrated the ability of the supplement AltilixBoth nutraceutical and placebo pills were provided by Bionap S.R.L. (Belpasso, Catania, Italy) and were identical in size, color, and consistency to ensure blinding of the participants. The supplement (active ingredients: 10–12% chlorogenic acid and derivates and 2–4% luteolin-7-glucoside and derivates) was obtained from the leaves of The study was conducted according to the Declaration of Helsinki in Italy at the Unit of Diabetes and Cardiovascular Prevention, University Hospital of Palermo for 6 months, and was registered at clinicaltrials.gov (NCT03444558). The study was approved by the Research Ethics Committee of the University Hospital of Palermo (approval number 05/2017 on 10 May 2017). All subjects included in the study provided written informed consent. All subjects received the Altilix